Industry Reports
Catalent Acquires Accucaps To Expand Softgel Development And Manufacturing Capabilities And Capacity
Catalent Inc the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products announced that it has agreed to acquire Accucaps Industries Limited (Accucaps). The Canada-based developer and manufacturer of...
Industry Reports
Arrow Generiques to acquire select assets in France from Teva
Arrow Generiques SAS, the French subsidiary of Aurobindo Pharma Ltd announced the signing of an agreement to acquire select commercial products in France from Teva. Arrow Generiques will acquire the right, title and interest in products...
Industry Reports
GSK Starts Phase III Programme with Daprodustat for Anemia Associated with Chronic Kidney Disease
GlaxoSmithKline plc announced the start of a phase III development programme investigating daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), as a treatment for anaemia associated with chronic kidney disease (CKD). The phase III programme...
Industry Reports
Lilly Announces Top-Line Results of Solanezumab Phase 3 Clinical Trial
Eli Lilly and Company announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease (AD). Patients treated...
Industry Reports
Sun Pharma to acquire Biosintez in RussiaÂ
Sun Pharma announced the execution of definitive agreements by its wholly owned subsidiary, for the acquisition of 85.1% of JSC Biosintez, a Russian pharmaceutical company engaged in manufacture and marketing of pharmaceutical products in Russia and CIS region. ...
Industry Reports
Novartis acquires Selexys Pharmaceuticals Corporation and SelG1 antibody for reduction of pain crises in sickle cell disease (SCD)
Novartis announced it has acquired Selexys Pharmaceuticals Corporation, a company specializing in development of therapeutics in certain hematologic and inflammatory disorders. Novartis exercised its right to acquire Selexys following receipt of results of the SUSTAIN study,...
Industry Reports
Cumberland Pharmaceuticals Acquires U.S. Rights to Nordic Group’s Methotrexate Injection Products
Cumberland Pharmaceuticals , a U.S. specialty pharmaceutical company has entered into an Agreement to acquire the exclusive U.S. rights to Nordic Group B.V.'s innovative injectable methotrexate product line. The products are designed for the treatment of...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
